Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results of the ISAR-SHOCK registry

Thrombosis and Haemostasis

Volumn 112, Issue 6, 2014, Pages 1190-1197

  Orban, Martin ^a   Mayer, Katharina ^b   Morath, Tanja ^b   Bernlochner, Isabell ^c   Hadamitzky, Martin ^b   Braun, Siegmund ^b   Schulz, Stefanie ^b,e   Hoppmann, Petra ^c   Hausleiter, Jörg ^a   Tiroch, Klaus ^d   Mehilli, Julinda ^a,e   Schunkert, Heribert ^b,e   Massberg, Steffen ^a,e   Laugwitz, Karl Ludwig ^c,e   Sibbing, Dirk ^a,e   Kastrati, Adnan ^b,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HELIOS KLINIKUM WUPPERTAL   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Bleeding; Cardiogenic shock; Clopidogrel; Mortality; Prasugrel

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; P2RY12 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLEEDING; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CORONARY THROMBOSIS; DRUG EFFECTS; FEMALE; GERMANY; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; RECURRENT DISEASE; REGISTER; RISK FACTOR; SHOCK, CARDIOGENIC; THROMBOCYTE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CORONARY THROMBOSIS; FEMALE; GERMANY; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RECURRENCE; REGISTRIES; RISK FACTORS; SHOCK, CARDIOGENIC; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84914145142     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-06-0489     Document Type: Article

References (28)

1. Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–2619.
2. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501–2555.
3. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85: 92–93.
4. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908–2913.
5. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.
6. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after Clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–856.
7. Baue AE, Faist E, Fry D. Multiple organ failure - pathopyhsiology, prevention and therapy. Springer, Berlin, Heidelberg, New York2000 2000; XXII: 712 p.
8. Osmancik P, Jirmar R, Hulikova K, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158–166.
9. Bjelland TW, Hjertner O, Klepstad P, et al. Antiplatelet effect of Clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2010; 81: 1627–1631.
10. Ibrahim K, Christoph M, Schmeinck S, et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2014; 85: 649–656.
11. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.
12. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.
13. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287–1296.
14. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625–634.
15. Mayer K, Schulz S, Bernlochner I, et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost 2014; 112: 342–351.
16. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: acase for standardized definitions. Circulation 2007; 115: 2344–2351.
17. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933.
18. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of Clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8:250–256.
19. Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317–318.
20. TRIUMPH Investigators, Alexander JH, Reynolds HR, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. J Am Med Assoc 2007; 297: 1657–1666.
21. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with Clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–731.
22. Hasdai D, Holmes DR, Jr., Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J 1999; 138:21–31.
23. Zeymer U, Vogt A, Zahn R, et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 2004; 25: 322–328.
24. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467–473.
25. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303–1313.
26. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999–1010.
27. Montalescot G, Lassen JF, Hamm CW, et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J 2013; 165: 515–522.
28. Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases Clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630–635.